Eton Pharmaceuticals files FDA supplement to expand Khindivi to under-5s
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
July 29, 2026 6:50 AM EDTFDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency marketNew formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE®Submission allows for a potential first half 2027 approval of the expanded indication
DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Eton or the Company) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing... More
